Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : NOVARTIS
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A phase Ib study investigating the combination of RAD001 with trastuzumab and vinorelbine in patients with HER2- overexpressing metastatic breast cancer
To establish the feasible dose levels/regimens of RAD001 combined with weekly trastuzumab and vinorelbine HV therapy in patients with HER2-overexpressing metastatic breast cancer whose disease pr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A multi-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis
To assess the efficacy of oral STI571 in skin fibrosis in systemic sclerosis (SSc) patients as measured by an improvement in the modified Rodnan Skin Score. To assess the safety and tolerability of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of Elidel Cream 1% in mild to moderate head and neck atopic dermatitis of patients intolerant of topical corticosteroids
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
“An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” Studio in aperto, multicentrico, di accesso allargato a fingolimod in pazienti con sclerosi multipla recidivante-remittente, per i quali non esiste una adeguata alternativa terapeutica
The objectives of the study are: - provide early access to fingolimod to patients who have been diagnosed with relapsing-remitting multiple sclerosis and for whom no suitable therapy exists i.e where...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant use of ASM 981 (pimecrolimus) cream 1% (BID) plus topical corticosteroid (BID) for the treatment of severe atopic dermatitis in patients 2 to 17 years of age
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
Open-label, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease Studio multicentrico, in aperto per valutare la sicurezza/tollerabilita' ed efficacia di un trattamento della durata di 10 settimane con LCI699 in pazienti con malattia di Cushing
To assess the effects of 10 weeks treatment of LCI699 on 24 hour urine free cortisol (UFC) in patients with Cushing’s disease. Valutare gli effetti di 10 settimane di trattamento con LCI699 sul...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A multicenter, randomized, open label study to compare the development of liver fibrosis at 12 months after transplantation for hepatitis C cirrhosis in patients receiving either Neoral or tacrolimus Studio multicentrico, randomizzato, in aperto per confrontare lo sviluppo di fibrosi epatica 12 mesi dopo trapianto di fegato per cirrosi da epatite C in pazienti in trattamento con Neoral o tacrolimus -studio ``REFINE``
To demonstrate that the rate of fibrosis stage 2 or above (Ishak-Knodell FS≥2) at 1 year posttransplant is lower in hepatitis C positive patients receiving Neoral versus tacrolimus. Dimos...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A double-blind, randomized, multicenter 8 weeks study to evaluate the efficacy and safety of of valsartan / amlodipine combination based therapy versus amlodipine monotherapy based therapy in patients with stage II hypertension
To demonstrate superior efficacy of the combination of valsartan/amlodipine 160/10 mg, in patients with stage II hypertension, by testing the hypothesis that valsartan/amlodipine 160/10 mg produces su...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS)
To assess if canakinumab induces complete or almost complete response in patients with active TRAPS at Day 15 (defined as 15 days after the first dose).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed dose combination therapy of vildagliptin/metformin to individual monotherapies in drug na ve patients with type 2 diabetes
To demonstrate the efficacy of initial fixed combination treatment with vildagliptin and metformin in drug na ve patients with T2DM by testing the hypotheses that the HbA1c reduction with fixed combin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
Suivant